STABILITY OF CATAPLEXY OVER SEVERAL MONTHS - INFORMATION FOR THE DESIGN OF THERAPEUTIC TRIALS

被引:34
作者
GELB, M
GUILLEMINAULT, C
KRAEMER, H
LIN, S
MOON, S
DEMENT, WC
MIGNOT, E
机构
[1] STANFORD UNIV,SCH MED,CTR SLEEP WAKE DISORDERS,PALO ALTO,CA 94304
[2] STANFORD UNIV,CTR MED,DEPT PSYCHIAT,PALO ALTO,CA
关键词
CATAPLEXY; NARCOLEPSY; ANTICATAPLECTIC MEDICATIONS; THERAPEUTIC TRIALS;
D O I
10.1093/sleep/17.3.265
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Twenty-seven narcoleptic patients severely affected with cataplexy completed four symptom diaries over a 4-month period in order to clarify some of the controversies surrounding assessment of anticataplectic medications. The home diary method was found to be a viable model for the assessment of anticataplectic activity. Assessment of reliability in 1-, 2-, 3-, 4-, 5- and 10-day intervals indicated that reliability increases with the number of days included. A 10-day design was found to be optimal. Reliability decreased, however, with each successive diary over the 4-month period. Power analysis indicates that two groups of 30-40 subjects in a parallel design, or one group of 30-40 subjects in a crossover design, would be sufficient to demonstrate a significant therapeutic anticataplectic effect in most cases. A ''first diary effect'' was observed, suggesting that a training period prior to the actual trial might improve reliability. Whether the patient was treated or untreated with stimulant medications did not affect severity or fluctuation of cataplexy, suggesting that both groups of patients could be included in therapeutic trials. No time-of-day fluctuation was observed in the daily distribution of cataplexy attacks. Sudden increases in cataplexy were often, although not always, caused by unusual emotional events or sleepiness. The finding of a long-lasting ''precataplectic'' feeling or ''aura'' pointed to the need to carefully clarify the symptom prior to beginning a therapeutic trial.
引用
收藏
页码:265 / 273
页数:9
相关论文
共 29 条
[1]  
AKIMOTO H, 1960, DIS NERV SYST, V21, P1
[2]  
ALDRICH MS, 1992, NEUROLOGY, V42, P34
[3]  
Cataplexy Guilleminault C., 1976, NARCOLEPSY, P125
[4]  
Daniels LE, 1934, MEDICINE, V13, P1
[5]   INHIBITION OF UPTAKE OF TRITIATED-NORADRENALINE IN INTACT RAT BRAIN BY IMIPRAMINE + STRUCTURALLY RELATED COMPOUNDS [J].
GLOWINSKI, J ;
AXELROD, J .
NATURE, 1964, 204 (496) :1318-&
[6]   VILOXAZINE HYDROCHLORIDE IN NARCOLEPSY - A PRELIMINARY-REPORT [J].
GUILLEMINAULT, C ;
MANCUSO, J ;
SALVA, MAQ ;
HAYES, B ;
MITLER, M ;
POIRIER, G ;
MONTPLAISIR, J .
SLEEP, 1986, 9 (01) :275-279
[7]   STUDY ON CATAPLEXY [J].
GUILLEMINAULT, C ;
WILSON, RA ;
DEMENT, WC .
ARCHIVES OF NEUROLOGY, 1974, 31 (04) :255-261
[8]   NARCOLEPSY-CATAPLEXY .1. CLINICAL AND ELECTROPHYSIOLOGIC CHARACTERISTICS [J].
KALES, A ;
CADIEUX, RJ ;
SOLDATOS, CR ;
BIXLER, EO ;
SCHWEITZER, PK ;
PREY, WT ;
VELABUENO, A .
ARCHIVES OF NEUROLOGY, 1982, 39 (03) :164-168
[9]  
KRAEMER HC, 1987, MANY SUBJECTS STATIS
[10]   FLUOXETINE IN THE TREATMENT OF CATAPLEXY [J].
LANGDON, N ;
SHINDLER, J ;
PARKES, JD ;
BANDAK, S .
SLEEP, 1986, 9 (02) :371-373